SEB Asset Management AB Purchases Shares of 31,235 Solventum Corporation $SOLV

SEB Asset Management AB acquired a new position in Solventum Corporation (NYSE:SOLV) in the first quarter, HoldingsChannel reports. The institutional investor acquired 31,235 shares of the company’s stock, valued at approximately $2,040,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CrossGen Wealth LLC bought a new position in Solventum in the 4th quarter worth $25,000. Measured Wealth Private Client Group LLC bought a new stake in Solventum during the third quarter valued at about $25,000. JNBA Financial Advisors lifted its position in shares of Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after acquiring an additional 228 shares in the last quarter. CYBER HORNET ETFs LLC purchased a new position in shares of Solventum in the second quarter valued at about $28,000. Finally, Modus Advisors LLC bought a new position in shares of Solventum in the fourth quarter worth about $30,000.

Analysts Set New Price Targets

Several analysts recently issued reports on SOLV shares. UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Thursday, May 14th. BTIG Research restated a “buy” rating and set a $91.00 target price on shares of Solventum in a research report on Monday, July 13th. Wells Fargo & Company cut their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. KeyCorp boosted their price target on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Wedbush assumed coverage on shares of Solventum in a report on Friday, May 15th. They set an “outperform” rating and a $94.00 price objective for the company. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Solventum currently has an average rating of “Hold” and an average price target of $81.91.

Solventum Price Performance

SOLV stock opened at $77.29 on Friday. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $88.20. The firm has a market capitalization of $13.39 billion, a P/E ratio of 9.47, a price-to-earnings-growth ratio of 1.20 and a beta of 0.66. The company has a fifty day simple moving average of $77.39 and a two-hundred day simple moving average of $74.20. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.